debt_leverage_profile
0.03x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; debt-free clinical-stage biotech funded by equity; rising rates increase future capital raise dilution risk
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Reliance on European GMP biologics CDMOs (e.g., Germany/Austria); 2) US-China tension risk for API raw material sourcing
Inferred
Agent_Inference
international_expansion_readiness
No commercial revenue; pre-revenue clinical stage; no material sovereign currency devaluation exposure currently
Inferred
Agent_Inference
geographic_footprint
Operations primarily US-based; clinical trials in EU and Israel; minimal direct FX revenue exposure at this stage
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CDMO manufacturing dependency for SNS-301 and pipeline candidates likely exceeds 30% of operational input; non-substitutable short-term
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharmaceutical; no cloud-dependent revenue engine; cloud termination would disrupt data/operations but not revenue
Inferred
Agent_Inference
business_model_type_secondary
Secondary R&D informatics and trial data management would be impaired; backup feasible within 60-90 days via alternative providers
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; no external API-driven product; internal R&D platforms have moderate switching cost if CRO/CDMO systems are integrated
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; equity-funded biotech with no token issuance or profit-sharing instruments; revenue model is traditional drug commercialization
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure from EU clinical trial patient data; CCPA exposure limited; requires DPA agreements with EU trial sites
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal antitrust risk; small-cap pre-commercial biotech with no market dominance; niche cancer immunotherapy focus
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
0% recurring revenue currently; 100% transactional/milestone-based potential from partnerships; no commercial product approved
Inferred
Agent_Inference
monetization_vector
Future monetization via drug sales, licensing milestones, and partnership royalties; no current commercial revenue stream
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; oncology biologics typically priced $100K-$200K/year; pricing power contingent on clinical efficacy data
Inferred
Agent_Inference
pricing_power_rating
Potentially high if Phase 2/3 trials succeed in HPV+ cancers; orphan/niche oncology commands premium pricing with limited competition
Inferred
Agent_Inference
target_gross_margin_bracket
Target 70-85% gross margin post-commercialization, typical for biotech biologics; currently negative margins in development phase
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage issue; pre-commercial stage; future patients require prescriptions, eliminating free-rider dynamics
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth will be sublinear to headcount post-commercialization; partnering/licensing model reduces need for large commercial workforce
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth low post-approval if partnered; high during clinical development phase due to trial and manufacturing costs
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company is not a franchise model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics improve via oncologist KOL networks and hospital formulary adoption; partnership distribution reduces CAC burden
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; biotech drug value is clinical efficacy-driven, not network-dependent
Inferred
Agent_Inference
asset_efficiency_ratio
-92.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-high resilience; oncology treatments are non-discretionary; but funding/partnership activity sensitive to risk-off environments
Inferred
Agent_Inference
customer_segment_primary
Oncologists and cancer treatment centers prescribing HPV-associated cancer therapies; hospital and academic medical center formularies
Inferred
Agent_Inference
customer_segment_secondary
Biopharmaceutical licensing partners and potential acquirers seeking immuno-oncology pipeline assets
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital deployed toward clinical trial execution and CDMO manufacturing; no legacy infrastructure reallocation; pure forward-state R&D investment
Inferred
Agent_Inference
sec_cik
0001829802
High
SEC-EDGAR
ticker
SNSE
High
SEC-EDGAR